TERNS PHARMACEUTICALS, INC. (TERN)
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
📈 **POSITIVE** • Medium confidence analysis (71%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (84%) **Content type:** Clinical